Hospira (HSP) in Focus Following Positive News Coverage

Hospira (NYSE: HSP) shares could rise in anticipation of an FDA inspection of its Rocky Mountain drug-manufacturing facility last his year, according to some watchers. In 2010 the company received a letter from the FDA saying it was in violation of quality standards. Since then the company spent $300 million and is gearing up for inspections and potential clearance from the FDA in the first half of 2012. The Rocky Mountain facility is at operating at 60 to 70 percent utilization, and investors believe a ramp up could pave the way for upside in the stock. The stock was featured in a weekend article in Barron's.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
• Texas Instruments (TXN) jumps on first above-consensus guide in seven years
• European stocks rise; Tesla earnings boost global sentiment